HPV Status-Guided CDK and PI3K Inhibitor Selection for Head and Neck Cancer
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatment options for head and neck cancers lack specificity, as they do not effectively account for the varying genetic alterations present in cancers, such as those caused by HPV status, leading to suboptimal treatment responses.
Innovation Solution
Determining the HPV status of a subject with head and neck cancer to tailor treatment with either a CDK inhibitor for HPV-negative patients or a PI3K inhibitor for HPV-positive patients, based on the presence of specific genetic alterations in cell cycle or PI3K pathway genes, without the need for extensive genomic profiling.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current standard cancer treatment options are used for head and neck cancers, then treatment can be administered to all patients, but treatment effectiveness is suboptimal due to lack of specificity for varying genetic alterations
Solution Approach 1:
The patent segments the head and neck cancer patient population into distinct groups based on HPV status (positive or negative). This segmentation allows for tailored treatment approaches: HPV-positive patients receive one treatment regimen while HPV-negative patients receive another, thereby improving treatment effectiveness for each subgroup without requiring complex genomic profiling for all patients.
Solution Approach 2:
The patent performs preliminary determination of HPV status in patients before initiating treatment. By establishing the HPV status upfront, clinicians can pre-select the appropriate treatment pathway (CDK inhibitor for HPV-negative, other regimens for HPV-positive), avoiding the need for extensive subsequent genomic analysis and enabling immediate personalized treatment decisions.
2Adaptability or versatility
If extensive genomic profiling is performed to identify specific genetic alterations, then treatment can be highly personalized, but the complexity and cost of treatment evaluation increases significantly
Solution Approach 1:
The patent extracts and focuses on a single critical biomarker (HPV status) that serves as a proxy for underlying genetic alterations. Instead of performing comprehensive genomic profiling to detect multiple genetic variations, the invention isolates HPV status determination as the key diagnostic step, thereby achieving treatment personalization with significantly reduced complexity while still enabling identification of patients likely to respond to specific therapies.
Data Source
AI summary
Methods of treating a head and neck cancer are disclosed.